NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.